An open‐label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people

• Main Authors: Jingcheng Chen (Author), Jiangshuo Li (Author), Jingxuan Wu (Author), Yuqin Song (Author), Lijun Li (Author), Jianxiong Zhang (Author), Ruihua Dong (Author)
• Format: Book
• Published: Wiley, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract A drug-drug interaction (DDI) trial of cytochrome P450 3A (CYP3A) is a necessary part of early‐phase trials of drugs mainly metabolized by this enzyme, but CYP3A DDI clinical trials do not have a standard design, especially for Chinese people. We aimed to offer specific recommendations for...